184 related articles for article (PubMed ID: 31260137)
21. Linkage disequilibrium between the CYP2C19*17 allele and other clinically important CYP2C allelic variants in a healthy Scandinavian population.
Pedersen RS; Christensen MM; Brøsen K
Eur J Clin Pharmacol; 2012 Oct; 68(10):1463-4. PubMed ID: 22476388
[No Abstract] [Full Text] [Related]
22. PharmVar GeneFocus: CYP2C9.
Sangkuhl K; Claudio-Campos K; Cavallari LH; Agundez JAG; Whirl-Carrillo M; Duconge J; Del Tredici AL; Wadelius M; Rodrigues Botton M; Woodahl EL; Scott SA; Klein TE; Pratt VM; Daly AK; Gaedigk A
Clin Pharmacol Ther; 2021 Sep; 110(3):662-676. PubMed ID: 34109627
[TBL] [Abstract][Full Text] [Related]
23. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes.
Karam WG; Goldstein JA; Lasker JM; Ghanayem BI
Drug Metab Dispos; 1996 Oct; 24(10):1081-7. PubMed ID: 8894508
[TBL] [Abstract][Full Text] [Related]
24. Investigation of enzyme selectivity in the human CYP2C subfamily: homology modelling of CYP2C8, CYP2C9 and CYP2C19 from the CYP2C5 crystallographic template.
Lewis DF; Dickins M; Lake BG; Goldfarb PS
Drug Metabol Drug Interact; 2003; 19(4):257-85. PubMed ID: 14768974
[TBL] [Abstract][Full Text] [Related]
25. Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation.
Goh LL; Lim CW; Sim WC; Toh LX; Leong KP
PLoS One; 2017; 12(1):e0169233. PubMed ID: 28046094
[TBL] [Abstract][Full Text] [Related]
26. Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes.
Lundblad MS; Stark K; Eliasson E; Oliw E; Rane A
Biochem Biophys Res Commun; 2005 Feb; 327(4):1052-7. PubMed ID: 15652503
[TBL] [Abstract][Full Text] [Related]
27. Impact of genetic polymorphisms in CYP2C9 and CYP2C19 on the pharmacokinetics of clinically used drugs.
Hirota T; Eguchi S; Ieiri I
Drug Metab Pharmacokinet; 2013; 28(1):28-37. PubMed ID: 23165865
[TBL] [Abstract][Full Text] [Related]
28. Distribution of a novel
Fernandes VC; Pretti MAM; Tsuneto LT; Petzl-Erler ML; Suarez-Kurtz G
Front Genet; 2023; 14():1114742. PubMed ID: 37025454
[TBL] [Abstract][Full Text] [Related]
29. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
[TBL] [Abstract][Full Text] [Related]
30. Comparison of cytochrome P450 2C subfamily members in terms of drug oxidation rates and substrate inhibition.
Niwa T; Yamazaki H
Curr Drug Metab; 2012 Oct; 13(8):1145-59. PubMed ID: 22571484
[TBL] [Abstract][Full Text] [Related]
31. Nanopore sequencing of the pharmacogene
Liau Y; Maggo S; Miller AL; Pearson JF; Kennedy MA; Cree SL
Pharmacogenomics; 2019 Sep; 20(14):1033-1047. PubMed ID: 31559921
[No Abstract] [Full Text] [Related]
32. Intergenic transcripts containing a novel human cytochrome P450 2C exon 1 spliced to sequences from the CYP2C9 gene.
Warner SC; Finta C; Zaphiropoulos PG
Mol Biol Evol; 2001 Oct; 18(10):1841-8. PubMed ID: 11557791
[TBL] [Abstract][Full Text] [Related]
33. The transcriptional regulation of the human CYP2C genes.
Chen Y; Goldstein JA
Curr Drug Metab; 2009 Jul; 10(6):567-78. PubMed ID: 19702536
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of cytochrome P450 enzymes from the CYP2C subfamily in the human brain.
Booth Depaz IM; Toselli F; Wilce PA; Gillam EM
Drug Metab Dispos; 2015 Mar; 43(3):353-7. PubMed ID: 25504503
[TBL] [Abstract][Full Text] [Related]
35. The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database.
Gaedigk A; Ingelman-Sundberg M; Miller NA; Leeder JS; Whirl-Carrillo M; Klein TE;
Clin Pharmacol Ther; 2018 Mar; 103(3):399-401. PubMed ID: 29134625
[TBL] [Abstract][Full Text] [Related]
36. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
37. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
[TBL] [Abstract][Full Text] [Related]
38. Induction of CYP2C genes in human hepatocytes in primary culture.
Gerbal-Chaloin S; Pascussi JM; Pichard-Garcia L; Daujat M; Waechter F; Fabre JM; Carrère N; Maurel P
Drug Metab Dispos; 2001 Mar; 29(3):242-51. PubMed ID: 11181490
[TBL] [Abstract][Full Text] [Related]
39. Genetic variation at the CYP2C locus and its association with torsemide biotransformation.
Vormfelde SV; Schirmer M; Toliat MR; Meineke I; Kirchheiner J; Nürnberg P; Brockmöller J
Pharmacogenomics J; 2007 Jun; 7(3):200-11. PubMed ID: 16969365
[TBL] [Abstract][Full Text] [Related]
40. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
